Acceleron Announces Preclinical Presentations on Sotatercept in Pulmonary Arterial Hypertension at the 2018 American Heart Association Scientific Session

CAMBRIDGE, Mass.–()–Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company
in the discovery and development of TGF-beta therapeutics to treat
serious and rare diseases, today announced plans to deliver three
preclinical presentations on sotatercept in Pulmonary Arterial
Hypertension (PAH) at the 2018 American Heart Association (AHA)
Scientific Session in Chicago, IL, November 10-12, 2018.

“The preclinical research we’ll be presenting at AHA describes
sotatercept’s ability to exert positive effects on key measures of
disease activity—including pulmonary vascular remodeling, pulmonary
arterial pressures, and ventricular hypertrophy—in well-established
animal models of PAH,” said Ravi Kumar, Chief Scientific Officer of
Acceleron. “Collectively, these findings support our belief that
sotatercept could not only improve overall pulmonary and cardiac
function but may also have disease-modifying potential.”

 

Presentations

 

Title:

   

ActRIIA-Fc Rebalances Activin/GDF and BMP9 Signaling to
Attenuate Experimental Pulmonary Hypertension
(Abstract: 320)

Session:

Cournand and Comroe Young Investigator Award Competition

Date:

Saturday, November 10th

Time:

2:45 – 2:55 p.m. CST (McCormick Place, S106a)

 

Title:

Sotatercept for rebalancing BMP/TGF-beta/activin signaling in
PAH

Session:

Novel Therapies for PAH: The next generation of Clinical Trials

Date:

Sunday, November 11th

Time:

9:45 – 9:55 a.m. CST (McCormick Place, N230a)

 

Title:

RAP-011, a Murine Ortholog of ActRIIA-Fc (Sotatercept),
Improves Pulmonary Hemodynamics and Restores Right Ventricular
Structure and Function in a Preclinical Model of Severe
Angio-Obliterative Pulmonary Arterial Hypertension
(Abstract:
16179)

Session:

New Insights into Right Ventricular Failure and Endothelial
Dysfunction in Pulmonary Hypertension

Date:

Sunday, November 11th

Time:

10:30 – 11:45 a.m. CST (McCormick Place, Zone 4)

 

The presentations will be available in the “Science” section on
Acceleron’s website, www.acceleronpharma.com,
immediately following their presentations at the conference. Acceleron
will also host and webcast a PAH Research and Development Deep
Dive event
on Friday, November 16, 2018.

Sotatercept is an investigational product that is not approved for any
use in any country.

About Sotatercept

Sotatercept is a ligand trap that is believed to increase BMPR2
signaling—the key molecular driver in all forms of PAH— through its
Activin+ approach of inhibiting multiple TGF-beta proteins. In multiple
pre-clinical and nonclinical studies, sotatercept demonstrated the
ability to attenuate pulmonary vascular muscularization, proliferation,
and right ventricular dysfunction. Sotatercept is currently being
evaluated in the PULSAR Phase 2 trial in PAH. For more information,
please visit www.clinicaltrials.gov.
Acceleron is also planning to initiate an exploratory PAH study known as
SPECTRA.

About PAH

PAH is a rare and chronic, rapidly progressing disorder characterized by
the constriction of small pulmonary arteries and elevated blood pressure
in the pulmonary circulation. PAH results in significant strain on the
heart, often leading to limited physical activity, heart failure, and
reduced life expectancy. The 5-year survival rate for patients with PAH
is approximately 57%. Available therapies generally act by promoting the
dilation of pulmonary vessels without addressing the underlying cause of
the disease. As a result, PAH often progresses rapidly for many patients
despite standard of care treatment. A growing body of research has
implicated imbalances in BMP and TGF-beta signaling as a primary driver
of PAH in familial, idiopathic and acquired forms of the disease.

About Acceleron

Acceleron is a Cambridge-based, clinical-stage biopharmaceutical company
dedicated to the discovery, development, and commercialization of
therapeutics to treat serious and rare diseases. The Company’s
leadership in the understanding of TGF-beta biology and protein
engineering generates innovative compounds that engage the body’s
ability to regulate cellular growth and repair.

Acceleron focuses its research and development efforts in hematologic,
neuromuscular, and pulmonary diseases. In hematology, the Company and
its global collaboration partner, Celgene, are developing luspatercept
for the treatment of chronic anemia in myelodysplastic syndromes,
beta-thalassemia, and myelofibrosis. Acceleron is also advancing its
neuromuscular franchise with two distinct Myostatin+ agents, ACE-083 and
ACE-2494, and a Phase 2 pulmonary program with sotatercept in pulmonary
arterial hypertension.

For more information, please visit www.acceleronpharma.com.
Follow Acceleron on social media: @AcceleronPharma and
LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements about the
Company’s strategy, future plans and prospects, including statements
regarding the development of the Company’s compounds, the timeline for
clinical development and regulatory approval of the Company’s compounds
and the expected timing for reporting of data from ongoing clinical
trials. The words “anticipate,” “believe,” “could,” “estimate,”
“expect,” “goal,” “intend,” “may,” “plan,” “potential,” “project,”
“should,” “target,” “will,” “would,” and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words.

Actual results could differ materially from those included in the
forward-looking statements due to various risks and uncertainties,
including, but not limited to, that preclinical testing of the Company’s
compounds and data from clinical trials may not be predictive of the
results or success of ongoing or later clinical trials, that the
development of the Company’s compounds will take longer and/or cost more
than planned, that the Company or its collaboration partner, Celgene,
will be unable to successfully complete the clinical development of the
Company’s compounds, that the Company or Celgene may be delayed in
initiating, enrolling or completing any clinical trials, and that the
Company’s compounds will not receive regulatory approval or become
commercially successful products. These and other risks and
uncertainties are identified under the heading “Risk Factors” included
in the Company’s most recent Annual Report on Form 10-K, and other
filings that the Company has made and may make with the SEC in the
future.

The forward-looking statements contained in this press release are based
on management’s current views, plans, estimates, assumptions and
projections with respect to future events, and the Company does not
undertake and specifically disclaims any obligation to update any
forward-looking statements.

Leave a Reply

Your email address will not be published. Required fields are marked *